-
Elevate Campuses IPO | The initial public offering consists of entirely fresh issue by the company with no offer-for-sale component.
-
Vishvaraj Environment IPO | The company proposed to issue fresh shares worth Rs 1,250 crore, while only promoter entity Premier Financial Services plans to offload Rs 1,000 crore worth shares via offer-for-sale.
-
The Mumbai-based company's Rs 230-crore IPO will conclude on October 1
-
Logistics service provider Glottis said on September 26 that it has mobilised a little over Rs 55 crore from anchor investors
-
It can be tempting to draw parallels and make comparisons between prominent companies, especially those under the same corporate umbrella. For example, while evaluating the IPO prospects of PhonePe (which has filed for a mega Rs 12,000 crore IPO), versus Flipkart, such direct comparisons can be misleading. These two entities, despite their shared Walmart parentage, operate on fundamentally different business models
-
In 2024, VISUfarma, backed by GHO Capital, reported a revenue of 48.1 million. It operates in all major European markets, including Italy, the UK, Spain, Germany, and France
-
Dhariwal Buildtech IPO | The public issue comprises of entirely fresh issue with no offer-for-sale component.
-
Laser Power & Infra IPO | The company proposed to issue fresh shares worth Rs 800 crore, while promoters will sell shares amounting to Rs 400 crore via offer-for-sale.
-
As per the draft papers, the proposed IPO is entirely an Offer for Sale (OFS) of up to 4.63 crore equity shares.
-
Bombay Coated and Special Steels IPO | The company proposed to raise entire funds by issuing 1.5 crore new shares with no offer-for-sale component.
-
Kusumgar IPO | The public issue comprises of entirely an offer-for-sale by promoters, with no fresh issue component.
-
A University of Cambridge scientist who examines and designs sustainable materials, hit upon the concept of bamboo bats a few years ago in the course of his work on the use of bamboo as a structural material for building homes and schools.
-
Kotak Mahindra Capital, ICICI Securities, HDFC Bank, Axis Capital and SBI Capital Markets are the book running lead managers to the issue. The equity shares are proposed to be listed on both BSE and NSE.
-
Rotomag Enertec IPO | The company proposed to mobilise Rs 500 crore by issuing new shares, while existing shareholders including promoters and investor BanyanTree will be selling up to 2.4 crore shares via offer-for-sale route.
-
Deon Energy IPO | The Ahmedabad-based company's maiden public offering is entirely a fresh issue of shares with no offer for sale component.
-
Parijat Industries IPO | The public issue comprises a fresh issue of shares worth Rs 160 crore and an offer for sale (OFS) of 2.04 crore shares by promoters and other existing shareholders.
-
HSBC outlines several mitigation strategies for Sun Pharma, including shifting manufacturing to CDMO partners with US-based plants.
-
“Few Indian pharma companies with exposure to non-U.S. domiciled branded formulation or innovator drug companies, who in turn export to the U.S., may face challenges,” said Deepak Jotwani, VP & Sector Head, ICRA.
-
Glottis IPO | The Tamil Nadu-based company aims to raise Rs 160 crore via fresh shares, while promoters will be selling 1.1 crore shares via offer-for-sale.
-
Aarvee Engineering Consultants IPO | The company plans to mobilise Rs 202.5 crore via fresh shares, while promoter Venkatachala Chakrapani Redla will be selling up to 67.5 lakh shares via offer-for-sale.
-
Om Freight Forwarders IPO | The public issue is a combination of fresh issuance of shares worth Rs 24.44 crore, and an offer-for-sale of 72.5 lakh shares worth Rs 97.88 crore at the upper price band.
-
Insurance giant LIC is likely to make a big bet on this issue with the anchor portion likely on October 3
-
Alcobrew Distilleries IPO | The company plans to raise Rs 258.3 crore by issuing fresh shares, while promoter Romesh Pandita will be selling 1.8 crore shares via offer-for-sale route.
-
While generic drugs are exempted from the latest action, companies still face uncertainty over tariffs due to an investigation by the US government under Section 232 to see whether pharma imports pose a threat to national security.
-
This values the company around $9 billion, the people said, significantly below the $15 billion it was expecting in December when the papers were filed the first time
